• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Evaluation of ceftriaxone (R013-9904) in the treatment of septicemia caused by gram-negative bacilli].

作者信息

Naessens A, Pierard D, Roels P, Lauwers S

出版信息

Pathol Biol (Paris). 1983 May;31(5):362-5.

PMID:6312398
Abstract

Thirty-four patients admitted for a suspicion of septicaemia were treated with ceftriaxone, a third generation cephalosporin. Ceftriaxone was administered IV at a dose of 2 grams daily, either as a single injection of 2 g or as two injections of 1 g each. 43 organisms were isolated from the blood of the 34 patients: 20 E.coli; 5 Klebsiella; 2 Salmonella; 2 indole positives Proteus; 1 indole negative Proteus; 1 Enterobacter; 2 Acinetobacter; 3 Staphylococcus aureus; 2 Streptococcus; 1 Enterococcus; 1 Meningococcus and 3 anaerobes. The MIC of the enterobacteria for ceftriaxone ranged from less than or equal to 0.097 microgram/ml to 1.56 microgram/ml. Only two staphylococci, one Acinetobacter and the enterococcus were resistant to the drug. Serum assays of ceftriaxone were performed on the second day of treatment for 15 patients. Within the group treated with a single dosis of 2 g per day, the blood levels were: maximal level (10 min, after the injection): 175 to 460 micrograms/ml (average: 315), minimal level (before injection) 12 to 100 micrograms/ml (average 53). Among the patients treated with two doses of 1 g per day, we obtained: maximal levels 121 to 260 micrograms/ml (average 178), minimal levels 31 to 70 micrograms/ml (average 52). A clinically favorable evolution was obtained for 29 patients (85%). In the cases of 4 patients, the antibiotherapy had to be adapted in view of the susceptibility of the organisms isolated. Ceftriaxone was very well tolerated. The only observed secondary effect was a drug fever occurring in 3 patients who remained febrile in spite of a general improvement.

摘要

相似文献

1
[Evaluation of ceftriaxone (R013-9904) in the treatment of septicemia caused by gram-negative bacilli].
Pathol Biol (Paris). 1983 May;31(5):362-5.
2
Ceftriaxone in the treatment of serious infections, particularly after surgery.头孢曲松用于治疗严重感染,尤其是术后感染。
Am J Surg. 1984 Oct 19;148(4A):35-40.
3
Interpretation of susceptibility testing of ceftriaxone.
Am J Med. 1984 Oct 19;77(4C):12-6.
4
[Use of cefotaxime in severe infections in newborn infants].[头孢噻肟在新生儿重症感染中的应用]
Pathol Biol (Paris). 1984 Dec;32(10):1040-2.
5
Single daily dose treatment of severe refractory infections with ceftriaxone. Cost savings and possible parenteral outpatient treatment.每日单次剂量使用头孢曲松治疗严重难治性感染。节省成本及可能的门诊胃肠外治疗。
Arch Intern Med. 1983 Oct;143(10):1868-73.
6
Ceftriaxone: therapeutic results in various infections and kinetic studies.
Arzneimittelforschung. 1984;34(3):321-5.
7
[Clinical evaluation of ceftriaxone in severe infections in adults].[头孢曲松用于成人严重感染的临床评估]
Pathol Biol (Paris). 1986 May;34(5):451-6.
8
Ceftriaxone therapy of meningitis and serious infections.头孢曲松治疗脑膜炎和严重感染。
Am J Med. 1984 Oct 19;77(4C):50-3.
9
Pharmacokinetics of ceftriaxone after intravenous infusion and intramuscular injection.静脉输注和肌内注射后头孢曲松的药代动力学
Am J Med. 1984 Oct 19;77(4C):112-6.
10
Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).针对儿科患者分离出的细菌进行的肠外广谱头孢菌素比较:哨兵抗菌监测计划(1998 - 2004年)报告
Diagn Microbiol Infect Dis. 2007 Jan;57(1):109-16. doi: 10.1016/j.diagmicrobio.2006.06.011. Epub 2006 Aug 23.

引用本文的文献

1
Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.头孢曲松。对其抗菌活性、药理特性及治疗用途的综述。
Drugs. 1984 Jun;27(6):469-527. doi: 10.2165/00003495-198427060-00001.